Search
Atlanta, GA Paid Clinical Trials
A listing of 1311 clinical trials in Atlanta, GA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 1311
There are currently 1311 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Recruiting
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of improvement (recurrent). APG-1252 is a drug that inhibits activity of proteins that prevent cell death, leading to increased cell death and reduced cell growth. Cobimetinib is used in patients whose cancer has a mutated (changed) form of a gene called BRAF. It is in a cla... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Advanced Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children \< 2 years of age genetically diagnosed with SMA.
Gender:
ALL
Ages:
Between 3 months and 24 months
Trial Updated:
06/13/2025
Locations: Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia
Conditions: Muscular Atrophy, Spinal
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Recruiting
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping the... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/13/2025
Locations: Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia
Conditions: Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
Recruiting
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Cystic Fibrosis
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
Recruiting
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues.
The main questions it aims to answer are:
1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and
2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Gender:
ALL
Ages:
3 months and below
Trial Updated:
06/13/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Post-ligation Cardiac Syndrome
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
ALL
Ages:
Between 5 years and 60 years
Trial Updated:
06/13/2025
Locations: Grady Health System, Atlanta, Georgia +5 locations
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/13/2025
Locations: Piedmont Pulmonary and Sleep Medicine Buckhead, Atlanta, Georgia
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia
Conditions: Low Grade Serous Ovarian Cancer
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
06/13/2025
Locations: Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia
Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Recruiting
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Grady Health System, Atlanta, Georgia +3 locations
Conditions: Extensive Stage Lung Small Cell Carcinoma
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
Recruiting
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are:
How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working?
Participants will receive a single dose of EPI-321 throu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Facioscapulohumeral Muscular Dystrophy
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Recruiting
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Multiple Myeloma
1 - 12 of 1311